Canada Pension Plan Investment Board decreased its holdings in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 41.4% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 59,779 shares of the specialty pharmaceutical company’s stock after selling 42,204 shares during the quarter. Canada Pension Plan Investment Board owned about 0.10% of Jazz Pharmaceuticals PLC worth $8,743,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds have also made changes to their positions in JAZZ. Toronto Dominion Bank lifted its stake in Jazz Pharmaceuticals PLC by 12.4% in the second quarter. Toronto Dominion Bank now owns 736 shares of the specialty pharmaceutical company’s stock worth $114,000 after acquiring an additional 81 shares during the period. US Bancorp DE lifted its stake in Jazz Pharmaceuticals PLC by 94.4% in the second quarter. US Bancorp DE now owns 758 shares of the specialty pharmaceutical company’s stock worth $118,000 after acquiring an additional 368 shares during the period. Gargoyle Investment Advisor L.L.C. purchased a new stake in Jazz Pharmaceuticals PLC in the second quarter worth $206,000. Janney Montgomery Scott LLC purchased a new stake in Jazz Pharmaceuticals PLC in the second quarter worth $211,000. Finally, Brighton Jones LLC purchased a new stake in Jazz Pharmaceuticals PLC in the second quarter worth $213,000. 88.52% of the stock is owned by institutional investors.
WARNING: “Jazz Pharmaceuticals PLC (JAZZ) Shares Sold by Canada Pension Plan Investment Board” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another domain, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this article can be accessed at https://www.dispatchtribunal.com/2017/11/12/jazz-pharmaceuticals-plc-jazz-shares-sold-by-canada-pension-plan-investment-board.html.
Shares of Jazz Pharmaceuticals PLC (JAZZ) opened at $138.70 on Friday. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.10 and a quick ratio of 2.49. Jazz Pharmaceuticals PLC has a 1-year low of $99.28 and a 1-year high of $163.75. The company has a market capitalization of $8,315.20, a P/E ratio of 17.40, a price-to-earnings-growth ratio of 0.84 and a beta of 1.00.
A number of brokerages recently commented on JAZZ. Royal Bank Of Canada reaffirmed a “buy” rating on shares of Jazz Pharmaceuticals PLC in a research note on Wednesday, August 9th. Deutsche Bank AG set a $178.00 price objective on Jazz Pharmaceuticals PLC and gave the company a “buy” rating in a research report on Monday, July 17th. Zacks Investment Research lowered Jazz Pharmaceuticals PLC from a “hold” rating to a “sell” rating in a research report on Friday. Piper Jaffray Companies reissued a “buy” rating and set a $177.00 price objective on shares of Jazz Pharmaceuticals PLC in a research report on Thursday, August 10th. Finally, Wells Fargo & Company reissued an “outperform” rating and set a $177.00 price objective (down previously from $178.00) on shares of Jazz Pharmaceuticals PLC in a research report on Thursday, August 10th. Two analysts have rated the stock with a sell rating, five have given a hold rating and eighteen have issued a buy rating to the company. Jazz Pharmaceuticals PLC presently has an average rating of “Buy” and an average target price of $180.13.
In other news, EVP Michael Patrick Miller sold 200 shares of the firm’s stock in a transaction that occurred on Tuesday, August 15th. The stock was sold at an average price of $144.38, for a total value of $28,876.00. Following the transaction, the executive vice president now owns 21,996 shares in the company, valued at $3,175,782.48. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Bruce C. Cozadd sold 1,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $153.52, for a total value of $153,520.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 3,855 shares of company stock worth $571,374. Company insiders own 4.30% of the company’s stock.
About Jazz Pharmaceuticals PLC
Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.
Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ).
Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.